#Canada #AGM #Toronto #Cardiol Therapeutics #CardiolRx

Overview of the AGM

On June 24, 2026, Cardiol Therapeutics Inc. held its Annual General Meeting (AGM) virtually, reflecting the company's commitment to transparency and shareholder engagement. The meeting provided an opportunity for shareholders to vote on several critical resolutions that would shape the company's direction in the coming year. With a notable majority, shareholders expressed overwhelming support for all management resolutions presented in the Management Information Circular dated May 7, 2026.

Board Elections and Auditor Appointment

The centerpiece of the AGM involved the election of directors. Proposed directors included many seasoned professionals: Dr. Guillermo Torre-Amione, David Elsley, Chris Waddick, Teri Loxam, Dr. Timothy Garnett, Jennifer Chao, Peter Pekos, and Colin Stott. Each nominee received a resounding majority of favoring votes, underscoring the confidence shareholders have in the leadership team. The results highlighted the following:

• - Dr. Guillermo Torre-Amione: 29,028,685 votes (96.45%)
• - David Elsley: 29,528,289 votes (98.11%)
• - Chris Waddick: 29,786,108 votes (98.96%)
• - Teri Loxam: 29,787,560 votes (98.97%)
• - Dr. Timothy Garnett: 29,855,359 votes (99.19%)
• - Jennifer Chao: 28,965,662 votes (96.24%)
• - Peter Pekos: 29,027,205 votes (96.44%)
• - Colin Stott: 29,785,651 votes (98.96%)

Following the board elections, shareholder support also extended to the appointment of BDO Canada LLP as the independent auditors for the current fiscal year, along with the authorization for the Board of Directors to determine the auditors' compensation.

Implications of the AGM Results

The decisive approval of the resolutions at the AGM emphasizes the strong belief shareholders hold in Cardiol's objectives, particularly its focus on developing innovative therapies for heart disease. The company's lead drug candidate, CardiolRx™, is designed to target inflammatory pathways crucial in diseases such as recurrent pericarditis and myocarditis.

Focused on Heart Health

Cardiol Therapeutics is at the forefront of developing anti-inflammatory and anti-fibrotic therapies aimed at chronic heart conditions. Their MAVERIC Program is particularly noteworthy, as it addresses recurrent pericarditis, a condition that affects many patients by causing persistent and debilitating symptoms. The Phase III MAVERIC trial is ongoing, showing promise in the treatment landscape for patients suffering from this condition. Furthermore, the ARCHER Program highlights CardiolRx™'s application in acute myocarditis, presenting a strategic avenue to mitigate a leading cause of cardiac issues, especially in young adults.

In addition to CardiolRx™, the introduction of the CRD-38 subcutaneous drug formulation aims to diversify Cardiol's therapeutic options, catering to a broader patient demographic experiencing heart-related inflammation.

Future Outlook

As Cardiol progresses with its clinical initiatives and navigates the complexities of product development, the strong backing from shareholders demonstrated at the AGM will be pivotal in achieving its long-term goals. Moving forward, Cardiol Therapeutics not only remains focused on enhancing the lives of individuals with heart disease but also strives to be a leader in life sciences through innovation and dedicated research.

The webcast of the AGM will be made available on Cardiol's investor relations website, ensuring that stakeholders can stay updated on the company's progress and strategic direction.

Conclusion

In conclusion, the outcomes from the AGM affirm that Cardiol Therapeutics is well-positioned on its path towards revolutionizing heart disease therapies. The strong votes of confidence, coupled with the company's ambitious programs, signify a promising future for patients grappling with chronic heart conditions and for the investors keen on supporting their transformative approach to healthcare.